In adults with overweight or obesity, continued weekly semaglutide after a 20-wk run-in improved weight loss.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 34339232.
- Also identified by DOI 10.7326/ACPJ202108170-088.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Rubino D, Abrahamsson N, Davies M, et al. <b>Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial.</b> JAMA. 2021;325:1414-25. 33755728.
Medical subject headings
- Overweight
- Weight Loss